NCCN task force report: Update on the management of patients with gastrointestinal stromal tumors

George D. Demetri; Margaret Von Mehren; Cristina R. Antonescu; Ronald P. DeMatteo; Kristen N. Ganjoo; Robert G. Maki; Peter W.T. Pisters; Chandrajit P. Raut; Richard F. Riedel; Scott Schuetze; Hema M. Sundar; Jonathan C. Trent; Jeffrey D. Wayne

doi:10.6004/jnccn.2010.0116

NCCN task force report: Update on the management of patients with gastrointestinal stromal tumors

George D. Demetri, Margaret Von Mehren, Cristina R. Antonescu, Ronald P. DeMatteo, Kristen N. Ganjoo, Robert G. Maki, Peter W.T. Pisters, Chandrajit P. Raut, Richard F. Riedel, Scott Schuetze, Hema M. Sundar, Jonathan C. Trent, Jeffrey D. Wayne

Surgical Oncology

Research output: Contribution to journal › Review article › peer-review

831 Scopus citations

Abstract

The standard of care for managing patients with gastrointestinal stromal tumors (GISTs) rapidly changed after the introduction of effective molecularly targeted therapies involving tyrosine kinase inhibitors (TKIs), such as imatinib mesylate and sunitinib malate. A better understanding of the molecular characteristics of GISTs have improved the diagnostic accuracy and led to the discovery of novel immunomarkers and new mechanisms of resistance to TKI therapy, which in turn have resulted in the development of novel treatment strategies. To address these issues, the NCCN organized a task force consisting of a multidisciplinary panel of experts in the fields of medical oncology, surgical oncology, molecular diagnostics, and pathology to discuss the recent advances, identify areas of future research, and recommend an optimal approach to care for patients with GIST at all stages of disease. The task force met for the first time in October 2003 and again in December 2006 and October 2009. This supplement describes the recent developments in the field of GIST as discussed at the October 2009 meeting.

Original language	English (US)
Pages (from-to)	S1-S40
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	8
Issue number	SUPPL. 2
DOIs	https://doi.org/10.6004/jnccn.2010.0116
State	Published - Apr 2010

Keywords

Abdominal tumor
CD117
GEP
GIST
Gastric mass
Gastrointestinal stromal tumor
Gastrointestinal tract
Gene expression profiling
Imatinib
KIT
Liver metastasis
NCCN
PDGFRA
Small bowel tumor
Stomach cancer
Sunitinib
TKIs
Tyrosine kinase inhibitors
Wild-type GISTs

ASJC Scopus subject areas

Oncology

Access to Document

10.6004/jnccn.2010.0116

Cite this

Demetri, G. D., Von Mehren, M., Antonescu, C. R., DeMatteo, R. P., Ganjoo, K. N., Maki, R. G., Pisters, P. W. T., Raut, C. P., Riedel, R. F., Schuetze, S., Sundar, H. M., Trent, J. C., & Wayne, J. D. (2010). NCCN task force report: Update on the management of patients with gastrointestinal stromal tumors. JNCCN Journal of the National Comprehensive Cancer Network, 8(SUPPL. 2), S1-S40. https://doi.org/10.6004/jnccn.2010.0116

Demetri, GD, Von Mehren, M, Antonescu, CR, DeMatteo, RP, Ganjoo, KN, Maki, RG, Pisters, PWT, Raut, CP, Riedel, RF, Schuetze, S, Sundar, HM, Trent, JC & Wayne, JD 2010, 'NCCN task force report: Update on the management of patients with gastrointestinal stromal tumors', JNCCN Journal of the National Comprehensive Cancer Network, vol. 8, no. SUPPL. 2, pp. S1-S40. https://doi.org/10.6004/jnccn.2010.0116

@article{2ef92357903e40cfa8cbb4ffd2ce64a5,

title = "NCCN task force report: Update on the management of patients with gastrointestinal stromal tumors",

abstract = "The standard of care for managing patients with gastrointestinal stromal tumors (GISTs) rapidly changed after the introduction of effective molecularly targeted therapies involving tyrosine kinase inhibitors (TKIs), such as imatinib mesylate and sunitinib malate. A better understanding of the molecular characteristics of GISTs have improved the diagnostic accuracy and led to the discovery of novel immunomarkers and new mechanisms of resistance to TKI therapy, which in turn have resulted in the development of novel treatment strategies. To address these issues, the NCCN organized a task force consisting of a multidisciplinary panel of experts in the fields of medical oncology, surgical oncology, molecular diagnostics, and pathology to discuss the recent advances, identify areas of future research, and recommend an optimal approach to care for patients with GIST at all stages of disease. The task force met for the first time in October 2003 and again in December 2006 and October 2009. This supplement describes the recent developments in the field of GIST as discussed at the October 2009 meeting.",

keywords = "Abdominal tumor, CD117, GEP, GIST, Gastric mass, Gastrointestinal stromal tumor, Gastrointestinal tract, Gene expression profiling, Imatinib, KIT, Liver metastasis, NCCN, PDGFRA, Small bowel tumor, Stomach cancer, Sunitinib, TKIs, Tyrosine kinase inhibitors, Wild-type GISTs",

author = "Demetri, {George D.} and {Von Mehren}, Margaret and Antonescu, {Cristina R.} and DeMatteo, {Ronald P.} and Ganjoo, {Kristen N.} and Maki, {Robert G.} and Pisters, {Peter W.T.} and Raut, {Chandrajit P.} and Riedel, {Richard F.} and Scott Schuetze and Sundar, {Hema M.} and Trent, {Jonathan C.} and Wayne, {Jeffrey D.}",

year = "2010",

month = apr,

doi = "10.6004/jnccn.2010.0116",

language = "English (US)",

volume = "8",

pages = "S1--S40",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "SUPPL. 2",

}

TY - JOUR

T1 - NCCN task force report

T2 - Update on the management of patients with gastrointestinal stromal tumors

AU - Demetri, George D.

AU - Von Mehren, Margaret

AU - Antonescu, Cristina R.

AU - DeMatteo, Ronald P.

AU - Ganjoo, Kristen N.

AU - Maki, Robert G.

AU - Pisters, Peter W.T.

AU - Raut, Chandrajit P.

AU - Riedel, Richard F.

AU - Schuetze, Scott

AU - Sundar, Hema M.

AU - Trent, Jonathan C.

AU - Wayne, Jeffrey D.

PY - 2010/4

Y1 - 2010/4

N2 - The standard of care for managing patients with gastrointestinal stromal tumors (GISTs) rapidly changed after the introduction of effective molecularly targeted therapies involving tyrosine kinase inhibitors (TKIs), such as imatinib mesylate and sunitinib malate. A better understanding of the molecular characteristics of GISTs have improved the diagnostic accuracy and led to the discovery of novel immunomarkers and new mechanisms of resistance to TKI therapy, which in turn have resulted in the development of novel treatment strategies. To address these issues, the NCCN organized a task force consisting of a multidisciplinary panel of experts in the fields of medical oncology, surgical oncology, molecular diagnostics, and pathology to discuss the recent advances, identify areas of future research, and recommend an optimal approach to care for patients with GIST at all stages of disease. The task force met for the first time in October 2003 and again in December 2006 and October 2009. This supplement describes the recent developments in the field of GIST as discussed at the October 2009 meeting.

AB - The standard of care for managing patients with gastrointestinal stromal tumors (GISTs) rapidly changed after the introduction of effective molecularly targeted therapies involving tyrosine kinase inhibitors (TKIs), such as imatinib mesylate and sunitinib malate. A better understanding of the molecular characteristics of GISTs have improved the diagnostic accuracy and led to the discovery of novel immunomarkers and new mechanisms of resistance to TKI therapy, which in turn have resulted in the development of novel treatment strategies. To address these issues, the NCCN organized a task force consisting of a multidisciplinary panel of experts in the fields of medical oncology, surgical oncology, molecular diagnostics, and pathology to discuss the recent advances, identify areas of future research, and recommend an optimal approach to care for patients with GIST at all stages of disease. The task force met for the first time in October 2003 and again in December 2006 and October 2009. This supplement describes the recent developments in the field of GIST as discussed at the October 2009 meeting.

KW - Abdominal tumor

KW - CD117

KW - GEP

KW - GIST

KW - Gastric mass

KW - Gastrointestinal stromal tumor

KW - Gastrointestinal tract

KW - Gene expression profiling

KW - Imatinib

KW - KIT

KW - Liver metastasis

KW - NCCN

KW - PDGFRA

KW - Small bowel tumor

KW - Stomach cancer

KW - Sunitinib

KW - TKIs

KW - Tyrosine kinase inhibitors

KW - Wild-type GISTs

UR - http://www.scopus.com/inward/record.url?scp=77951875556&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951875556&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2010.0116

DO - 10.6004/jnccn.2010.0116

M3 - Review article

C2 - 20457867

AN - SCOPUS:77951875556

SN - 1540-1405

VL - 8

SP - S1-S40

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - SUPPL. 2

ER -

NCCN task force report: Update on the management of patients with gastrointestinal stromal tumors

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this